keyword
MENU ▼
Read by QxMD icon Read
search

Pramipexole

keyword
https://www.readbyqxmd.com/read/28520466/development-and-validation-of-a-highly-sensitive-gradient-chiral-separation-of-pramipexole-in-human-plasma-by-lc-ms-ms
#1
Marco Michi, Massimo Breda, Justin Keane Belardi, Steven Dworetzky, Lara Solazzo
AIM: Development of a high-sensitivity chiral LC-MS/MS method was required to evaluate a combination of pramipexole (S-PPX) and its enantiomer dexpramipexole (R-PPX) in a proposed clinical trial. The previously available methods suffered from low sensitivity for the (S)-enantiomer in the presence of the more abundant (R)-enantiomer. Based on the projected dosing regimen in the clinical trial, a 5000-fold improvement in sensitivity was required for the (S)-enantiomer. METHODOLOGY: Spiked human plasma samples were extracted by liquid-liquid extraction using ethyl acetate and injected onto a CHIRALPAK ID column under pH gradient conditions...
May 18, 2017: Bioanalysis
https://www.readbyqxmd.com/read/28515684/selegiline-ameliorates-depression-like-behavior-in-mice-lacking-the-cd157-bst1-gene-a-risk-factor-for-parkinson-s-disease
#2
Satoka Kasai, Toru Yoshihara, Olga Lopatina, Katsuhiko Ishihara, Haruhiro Higashida
Parkinson's disease (PD), a neurodegenerative disorder, is accompanied by various non-motor symptoms including depression and anxiety, which may precede the onset of motor symptoms. Selegiline is an irreversible monoamine oxidase-B (MAO-B) inhibitor, and is widely used in the treatment of PD and major depression. However, there are few reports about the effects of selegiline on non-motor symptoms in PD. The aim of this study was to explore the antidepressant and anxiolytic effects of selegiline, using CD157/BST1 knockout (CD157 KO) mouse, a PD-related genetic model displaying depression and anxiety, compared with other antiparkinsonian drugs and an antidepressant, and was to investigate the effects of selegiline on biochemical parameters in emotion-related brain regions...
2017: Frontiers in Behavioral Neuroscience
https://www.readbyqxmd.com/read/28514334/-anxiety-and-depressive-disorders-in-parkinson-s-disease
#3
G N Akhmadeeva, R V Magzhanov, G N Tayupova, A R Bajtimerov, I M Hidijatova
This review presents the most recent data of worldwide research on anxiety and depressive disorders in patients with Parkinson's disease. Their characteristics and epidemiology, pathogenetic and clinical features, methods of diagnosis and treatment are presented. Depression occurs in 40-50% of patients with PD, anxiety in 17-43% of patients. Pramipexole, a dopamine agonist, is only one drug recommended for depression treatment. Nortriptyline and desipramine, belonging to the group of tricyclic antidepressants (TCAs), are considered to be possibly effective...
2017: Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova
https://www.readbyqxmd.com/read/28480621/efficacy-and-safety-of-pramipexole-extended-release-in-parkinson-s-disease-a-review-based-on-meta-analysis-of-randomized-controlled-trials
#4
T Shen, R Ye, B Zhang
BACKGROUND AND PURPOSE: We performed a meta-analysis of randomized controlled trials to evaluate the efficacy and safety of pramipexole extended-release (pramipexole ER) versus pramipexole immediate-release (pramipexole IR) or placebo in Parkinson's disease. METHODS: We performed a systematic online search for clinical trials for pramipexole ER treatment up to 1 August 2016. We assessed differences in Unified Parkinson's Disease Rating Scale (UPDRS) scores, percentage of 'on' time or 'off' time, withdrawals, adverse events (AEs) and life quality between pramipexole ER and pramipexole IR or placebo...
June 2017: European Journal of Neurology: the Official Journal of the European Federation of Neurological Societies
https://www.readbyqxmd.com/read/28462585/pramipexole-modulates-interregional-connectivity-within-the-sensorimotor-network
#5
Zheng Ye, Anke Hammer, Thomas F Münte
Pramipexole is widely prescribed to treat Parkinson's disease but has been reported to cause impulse control disorders such as pathological gambling. Recent neurocomputational models suggested that D2 agonists may distort functional connections between the striatum and the motor cortex, resulting in impaired reinforcement learning and pathological gambling. To examine how D2 agonists modulate the striatal-motor connectivity, we carried out a pharmacological resting-state functional magnetic resonance imaging study with a double-blind randomized within-subject crossover design...
May 2017: Brain Connectivity
https://www.readbyqxmd.com/read/28425238/depression-and-parkinson-disease-prevalence-temporal-relationship-and-determinants
#6
Hale Yapici Eser, Hatice Ayşe Bora, Aslı Kuruoğlu
BACKGROUND/AIM: Comorbidity of depression in Parkinson disease (PD) is a major factor that changes patients' quality of life. However, the neurobiological and sociodemographic risk factors for this comorbidity are not well studied. In this study, we aimed to define the prevalence, temporal relationship, and psychosocial and clinical determinants of depression comorbid with PD. MATERIALS AND METHODS: Fifty-five PD patients were evaluated with SCID, a data form that assessed sociodemographic and PD-related variables, UPDRS III, HAM-D, HAM-A, MMSE, and the Apathy Evaluation Scale...
April 18, 2017: Turkish Journal of Medical Sciences
https://www.readbyqxmd.com/read/28415529/a-sensitive-voltammetric-detection-of-pramipexole-based-on-1-1-3-3-tetramethyldisilazanecarbon-nanotube-modified-electrode
#7
Saeede Amirighadi, Jahan Bakhsh Raoof, Fereshteh Chekin, Reza Ojani
A simple low-cost method is proposed to fabricate a functionalized multi-wall carbon nanotube (MWCNT) with 1,1,3,3-tetramethyldisilazane (TMDS) molecule. The techniques of scanning electron microscope (SEM) with electron diffraction and energy dispersive X-ray (EDAX) analysis were applied to characterize the functionalized TMDS-MWCNT. The results showed that a MWCNT with high functionalization of TMDS can be obtained using this simple method. A new nanostructure sensor was constructed based on a glassy carbon electrode modified with TMDS-MWCNT (TMDS-MWCNT/GCE)...
June 1, 2017: Materials Science & Engineering. C, Materials for Biological Applications
https://www.readbyqxmd.com/read/28411257/relief-of-pain-depressed-behavior-in-rats-by-activation-of-d1-like-dopamine-receptors
#8
Matthew F Lazenka, Kelen C Freitas, Sydney Henck, S Stevens Negus
Clinically significant pain often includes depression of both behavior and mesolimbic dopamine signaling. Indirect and/or direct dopamine receptor agonists may alleviate pain-related behavioral depression. To test this hypothesis, the present study compared effects of indirect and direct dopamine agonists in a preclinical assay of pain-depressed operant responding. Male Sprague-Dawley rats with chronic indwelling microelectrodes in the medial forebrain bundle were trained in an intracranial self-stimulation (ICSS) procedure to press a lever for pulses of electrical brain stimulation...
April 14, 2017: Journal of Pharmacology and Experimental Therapeutics
https://www.readbyqxmd.com/read/28399600/-stealing-as-an-impulse-control-disorder-associated-with-pramipexole-a-case-report-from-forensic-psychiatric-practice
#9
Christian Clemm von Hohenberg, Harald Dreßing
We report the case of a 48-year-old female whom we examined for legal culpability. The proband was taking the dopamine agonist pramipexole as a treatment for Parkinson's disease. In temporal association, she had committed numerous shoplifting offences.While pathological gambling, excessive shopping and hypersexuality have often been described as adverse effects of dopamine agonists, there are only few reports about impulsive stealing in this context.We discuss the synergy of the pharmacological effects with familial, biographic and social factors, suggesting a bio-psycho-social etiology...
April 2017: Psychiatrische Praxis
https://www.readbyqxmd.com/read/28398815/successful-treatment-of-a-child-with-difficult-to-treat-chronic-selective-mutism-using-pramipexole
#10
Ahmed Naguy
No abstract text is available yet for this article.
May 2017: Journal of Child and Adolescent Psychopharmacology
https://www.readbyqxmd.com/read/28374775/comparison-for-efficacy-and-tolerability-among-ten-drugs-for-treatment-of-parkinson-s-disease-a-network-meta-analysis
#11
Chuanjun Zhuo, Xiaodong Zhu, Ronghuan Jiang, Feng Ji, Zhonghua Su, Rong Xue, Yuying Zhou
Parkinson's disease (PD) is a long term disorder affects the central nervous system and we aim to determine the relative efficacy of the current available drugs used in PD. Firstly, we performed a systematic review in current literature and eligible studies were retrieved from online databases, relevant data were extracted. Efficacy of these medications was assessed by different Unified Parkinson's Disease Rating Scales (UPDRS). Mean difference (MD) and odds ratio (OR) were produced by pairwise or network meta-analysis (NMA)...
April 4, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28370340/a-randomized-trial-of-a-low-dose-rasagiline-and-pramipexole-combination-p2b001-in-early-parkinson-s-disease
#12
C Warren Olanow, Karl Kieburtz, Mika Leinonen, Lawrence Elmer, Nir Giladi, Robert A Hauser, Olga S Klepiskaya, David L Kreitzman, Mark F Lew, David S Russell, Shaul Kadosh, Pninit Litman, Hadas Friedman, Nurit Linvah, For The P B Study Group
BACKGROUND: Rasagiline and pramipexole act to improve striatal dopaminergic transmission in PD via distinct and potentially synergistic mechanisms. We performed a placebo-controlled study to determine whether 2 doses of a novel slow-release, low-dose combination of rasagiline and pramipexole (P2B001) are effective and have a good safety profile in patients with early untreated PD. METHODS: Previously untreated patients with early PD were randomized (1:1:1) to once-daily treatment with P2B001 (0...
April 3, 2017: Movement Disorders: Official Journal of the Movement Disorder Society
https://www.readbyqxmd.com/read/28320137/what-increases-the-risk-of-malnutrition-in-parkinson-s-disease
#13
Svetlana Tomic, Vlasta Pekic, Zeljka Popijac, Tomislav Pucic, Marta Petek, Tihana Gilman Kuric, Sanja Misevic, Ruzica Palic Kramaric
Parkinson's disease (PD) patients are at a higher risk of malnutrition. The prevalence has been estimated to 0-24%, while 3%-60% of PD patients are reported to be at risk of malnutrition. To date, there is no clear explanation for malnutrition in these patients. The aim of this study was to determine the prevalence of malnutrition and to analyze factors that influence its appearance. The Mini Nutritional Assessment (MNA) was used to determine normal nutritional status; at risk of malnutrition; and already malnourished status...
April 15, 2017: Journal of the Neurological Sciences
https://www.readbyqxmd.com/read/28318897/efficacy-of-off-label-augmentation-in-unipolar-depression-a-systematic-review-of-the-evidence
#14
REVIEW
Julia Kleeblatt, Felix Betzler, Laura L Kilarski, Tom Bschor, Stephan Köhler
Treatment of unipolar depression with currently available antidepressants is still unsatisfactory. Augmentation with lithium or second generation antipsychotics is an established practice in non-responders to antidepressant monotherapy, but is also associated with a substantial non-response rate and with non-tolerance. Based on a systematic review of the literature, including meta-analyses, randomized controlled trials (RCTs), non-randomized comparative studies and case studies, off-label augmentation agents (administered in addition to an antidepressant, without FDA approval for treatment of MDD) were identified and evaluated regarding their efficacy using levels of evidence...
March 16, 2017: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/28290500/pramipexole-restores-depressed-transmission-in-the-ventral-hippocampus-following-mptp-lesion
#15
Javier Castro-Hernández, Paul A Adlard, David I Finkelstein
The hippocampus has a significant association with memory, cognition and emotions. The dopaminergic projections from both the ventral tegmental area and substantia nigra are thought to be involved in hippocampal activity. To date, however, few studies have investigated dopaminergic innervation in the hippocampus or the functional consequences of reduced dopamine in disease models. Further complicating this, the hippocampus exhibits anatomical and functional differentiation along its dorso-ventral axis. In this work we investigated the role of dopamine on hippocampal long term potentiation using D-amphetamine, which stimulates dopamine release, and also examined how a dopaminergic lesion affects the synaptic transmission across the anatomic subdivisions of the hippocampus...
March 14, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28283756/dopamine-t-cells-and-multiple-sclerosis-ms
#16
REVIEW
Mia Levite, Franca Marino, Marco Cosentino
Dopamine is a key neurotransmitter that induces critical effects in the nervous system and in many peripheral organs, via 5 dopamine receptors (DRs): D1R-D5R. Dopamine also induces many direct and very potent effects on many DR-expressing immune cells, primarily T cells and dendritic cells. In this review, we focus only on dopamine receptors, effects and production in T cells. Dopamine by itself (at an optimal concentration of~0.1 nM) induces multiple function of resting normal human T cells, among them: T cell adhesion, chemotactic migration, homing, cytokine secretion and others...
March 10, 2017: Journal of Neural Transmission
https://www.readbyqxmd.com/read/28273839/parkinson-s-disease-from-pathogenesis-to-pharmacogenomics
#17
REVIEW
Ramón Cacabelos
Parkinson's disease (PD) is the second most important age-related neurodegenerative disorder in developed societies, after Alzheimer's disease, with a prevalence ranging from 41 per 100,000 in the fourth decade of life to over 1900 per 100,000 in people over 80 years of age. As a movement disorder, the PD phenotype is characterized by rigidity, resting tremor, and bradykinesia. Parkinson's disease -related neurodegeneration is likely to occur several decades before the onset of the motor symptoms. Potential risk factors include environmental toxins, drugs, pesticides, brain microtrauma, focal cerebrovascular damage, and genomic defects...
March 4, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/28265478/twice-daily-versus-once-daily-pramipexole-extended-release-dosage-regimens-in-parkinson-s-disease
#18
Ji Young Yun, Young Eun Kim, Hui-Jun Yang, Han-Joon Kim, Beomseok Jeon
This open-label study aimed to compare once-daily and twice-daily pramipexole extended release (PER) treatment in Parkinson's disease (PD). PD patients on dopamine agonist therapy, but with unsatisfactory control, were enrolled. Existing agonist doses were switched into equivalent PER doses. Subjects were consecutively enrolled into either once-daily-first or twice-daily-first groups and received the prescribed amount in one or two, respectively, daily doses for 8 weeks. For the second period, subjects switched regimens in a crossover manner...
2017: Parkinson's Disease
https://www.readbyqxmd.com/read/28264052/restless-legs-syndrome-augmentation-among-japanese-patients-receiving-pramipexole-therapy-rate-and-risk-factors-in-a-retrospective-study
#19
Masayoshi Takahashi, Shingo Nishida, Masaki Nakamura, Mina Kobayashi, Kentaro Matsui, Eiki Ito, Akira Usui, Yuichi Inoue
To investigate the rate of and risk factors for restless legs syndrome (RLS) augmentation in Japanese patients receiving pramipexole (PPX) treatment. Records of 231 consecutive patients with idiopathic RLS who received PPX therapy for more than one month in a single sleep disorder center were analyzed retrospectively. Augmentation was diagnosed based on the Max Planck Institute criteria; associated factors were identified by logistic regression analysis. Mean age at PPX initiation was 60.6 ± 14.9 years and mean treatment duration was 48...
2017: PloS One
https://www.readbyqxmd.com/read/28256707/dopaminergic-agents-in-the-treatment-of-bipolar-depression-a-systematic-review-and-meta-analysis
#20
A G Szmulewicz, F Angriman, C Samamé, A Ferraris, D Vigo, S A Strejilevich
OBJECTIVE: To systematically examine the effects of dopaminergic agents (modafinil, armodafinil, pramipexole, methylphenidate, and amphetamines) on bipolar depression outcomes. METHODS: Meta-analysis of randomized controlled trials was performed to assess the efficacy and safety of treatment with dopaminergic agents in bipolar depression. In a secondary analysis, findings from both randomized controlled trials and high-quality observational studies were pooled by means of meta-analytic procedures to explore dopaminergic treatment-related new mania...
June 2017: Acta Psychiatrica Scandinavica
keyword
keyword
32571
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"